omeros corp (OMER) Key Developments
Omeros Seeks Acquisitions
Jan 16 15
Omeros Corporation (NasdaqGM:OMER) is seeking acquisitions. Omeros Corporation has filed a Shelf Registration, the proceeds of which will be used for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies.
Omeros Corporation Announces Positive Data Using OMS721
Nov 19 14
Omeros Corporation announced positive data using OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine protease-2 (MASP-2) program, to inhibit thrombus formation in an ex vivo pathophysiologic system of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain. OMS721 is currently in a Phase 2 clinical program evaluating the drug's efficacy in treating TMAs, including aHUS. The data announced resulted from studies in a well-established experimental model of TMA aimed at assessing the potential therapeutic benefits of OMS721 in TMA using serum samples from aHUS patients with different etiologies obtained during the acute phase of disease as well as during remission. The experimental model is based on the finding that sera from aHUS patients promote the formation of thrombi on human microvascular endothelial cells, the defining pathological feature of TMA. The studies reported showed that OMS721 significantly inhibited thrombus formation when added to serum samples from aHUS patients obtained during the acute phase of disease (p<0.01) as well as during remission (p<0.0001). OMS721 was as effective at inhibiting thrombus formation as the positive control in the studies - soluble complement receptor 1, an agent that completely blocks the complement system. Omeros reported that OMS721 also significantly inhibited complement deposition compared to control treatment in an experimental ex vivo pathophysiologic system of complement activation in TMA, again using serum samples from aHUS patients obtained during the acute phase of disease (p<0.01) and during remission (p<0.001). Having demonstrated that the lectin pathway, and MASP-2 specifically, are involved in the pathophysiology of aHUS, Prof. Remuzzi and his team are currently conducting additional experiments to understand the mechanism by which OMS721 blocks ex vivo thrombus formation in aHUS and its effect on endothelial cells, platelets and the alternative pathway of complement.
Omeros Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014
Nov 10 14
Omeros Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of USD 0.214 million compared to USD 0.196 million a year ago. Loss from operations was USD 17.132 million compared to USD 13.434 million a year ago. Net loss was USD 18.327 million compared to USD 13.870 million a year ago. Basic and diluted net loss per share was USD 0.54 compared to USD 0.46 a year ago.
For the nine months, the company reported revenue of USD 0.359 million compared to USD 1.431 million a year ago. Loss from operations was USD 50.033 million compared to USD 36.614 million a year ago. Net loss was USD 52.960 million compared to USD 37.951 million a year ago. Basic and diluted net loss per share was USD 1.61 compared to USD 1.36 a year ago.
Omeros Corporation Announces Positive Data Using Derivative of OMS721 in Animal Model of Stroke
Nov 6 14
Omeros Corporation announced positive data using a derivative of OMS721 in animal model of stroke. OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2). MASP-2 is critical to the function of the lectin pathway, one of the principal components of the complement system, a key part of the immune response. Omeros controls the worldwide rights to MASP-2 inhibition and to all therapeutics targeting MASP-2. The study evaluated the effect of MASP-2 blockade on neurological deficits and the size of brain infarcts 48 hours after induction of an ischemic stroke. Compared to control antibody-treated mice, mice treated with MASP-2 antibody demonstrated significantly reduced neurological deficits 48 hours after an ischemic stroke. In addition, the infarcted area of the brain was significantly smaller in MASP-2 antibody-treated mice. A similar degree of protection was also observed in gene-targeted MASP-2-deficient mice, which showed significantly lesser neurological deficits and infarct sizes compared to wild-type control mice. OMS721 is currently being evaluated in a Phase 2 clinical trial in patients with complement-mediated thrombotic microangiopathies (TMAs), including atypical hemolytic uremic syndrome (aHUS), thrombotic thrombocytopenic purpura (TTP), and stem cell transplant-related TMAs. Thrombotic microangiopathies are a family of rare, debilitating and life-threatening disorders characterized by multiple thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain. Omeros expects to be able to release data later this month on the effect of OMS721 on thrombus formation in a human ex vivo pathophysiologic system of aHUS using serum from aHUS patients both in the acute phase and in remission.
Omeros Corporation to Report Q3, 2014 Results on Nov 10, 2014
Nov 4 14
Omeros Corporation announced that they will report Q3, 2014 results at 5:00 PM, Eastern Standard Time on Nov 10, 2014